-
公开(公告)号:US20240011066A1
公开(公告)日:2024-01-11
申请号:US18303451
申请日:2023-04-19
发明人: Shahram Misaghi , Amy Shen , Inn Huam Yuk , Gavin Christian Barnard , Simon Auslaender , Niels Bauer , Benedikt Oswald
CPC分类号: C12P21/02 , C12N15/907 , C12N15/11 , C12N9/93 , C12N9/22 , C12N9/1029 , C12Y203/01 , C12N9/86 , C12Y305/02006 , C12N2310/20 , C12N2800/80
摘要: Herein are reported modified mammalian cells wherein the expression of the MYC gene and one or more of the BAK, BAX, SIRT-1 and ICAM-1 genes has been reduced or eliminated as well as methods for the recombinant production of a heterologous polypeptide using a modified mammalian cell according to the current invention. Further reported are use of the reduction of the expression of the genes for increasing volumetric productivity, increasing cell volume, increasing viability and increasing the possible cultivation time without cell split.
-
2.
公开(公告)号:US20230366003A1
公开(公告)日:2023-11-16
申请号:US18324843
申请日:2023-05-26
发明人: Andrew D. ELLINGTON , Ross THYER
摘要: Recombinant bacterial cells are provided that comprise a stable non-canonical amino acid translation pathway. In some aspects, the bacteria comprise nucleic acids encoding a non-canonical amino acid translation pathway (e.g., a tRNA for incorporation of a non-canonical amino acid, such selenocysteine); a marker polypeptide that includes the non-canonical amino acid. Recombinant tRNA and selection marker coding sequences are likewise provided.
-
公开(公告)号:US20230190797A1
公开(公告)日:2023-06-22
申请号:US16627272
申请日:2018-07-02
IPC分类号: A61K35/17 , C12N9/48 , C07K14/705 , C07K14/725 , C07K16/28 , C07H19/16 , C07K16/30 , C12N9/86 , A61P31/12 , A61P31/04 , A61P29/00 , A61K45/06
CPC分类号: A61K35/17 , C12N9/485 , C07K14/70517 , C07K14/7051 , C07K16/2803 , C07K14/70578 , C07H19/16 , C07K16/3038 , C07K16/3053 , C12Y304/17011 , C12N9/86 , C12Y305/02006 , A61P31/12 , A61P31/04 , A61P29/00 , A61K45/06 , C07K2319/03 , C07K2317/622 , C07K2319/02
摘要: Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express an antigen-targeted chimeric antigen receptor and a prodrug converting enzyme for the treatment of inflammation, inflammatory diseases, or pathogenic infections.
-
公开(公告)号:US20230064173A1
公开(公告)日:2023-03-02
申请号:US17793014
申请日:2021-01-13
申请人: TIANJIN UNIVERSITY
发明人: Yan ZHANG , Peishan LI , Yang TONG , Yiling HU , Dazhi LIU
摘要: Provided are a xanthine amide hydrolase and the use thereof, particularly the use thereof for treating gout.
-
公开(公告)号:US20230049044A1
公开(公告)日:2023-02-16
申请号:US17793009
申请日:2021-01-13
申请人: TIANJIN UNIVERSITY
发明人: Yan ZHANG , Peishan LI , Yang TONG , Yiling HU , Dazhi LIU
摘要: Provided are a 4-ureido-5-carboxyl-imidazole-amide hydrolase and use thereof, particularly use in the treatment of gout.
-
公开(公告)号:US20220251624A1
公开(公告)日:2022-08-11
申请号:US17728812
申请日:2022-04-25
发明人: Manel CAMPS , Jennifer ALLEN
摘要: Direct detection of mutagenesis in prokaryotes by reversion of an inactivating mutation (reversion mutation assay), producing a quantitative signal for in vivo mutagenesis, may greatly reduce the amount of test chemicals and labor involved in these assays. Further, transcriptional coupling of β-lactamase reversion and GFP, translational fusion between β-lactamase and GFP with stop codon in GFP, and a novel dual reporter to monitor continuous mutagenesis may be used in methods described herein.
-
公开(公告)号:US11327079B2
公开(公告)日:2022-05-10
申请号:US16627710
申请日:2018-12-12
发明人: Kye Shin Park , Joon Sang Park , Eun Hee Lee , Dong Hwi Hwang , In Jung Ji , Jae Woo Roh , Jin Sung Ahn , Eun-Jeong Yoon , Ji Hye Ko
摘要: The present invention relates to a method of directly detecting, using a mass-spectrometry method, whether a microorganism contained in a sample is resistant to antibiotics, and a kit for detection used therewith. More particularly, the present invention relates to a method and kit for directly detecting an antibiotic hydrolase secreted by a microorganism resistant to antibiotics, thereby directly determining whether the microorganism is resistant to antibiotics. According to the present invention, it is possible to very simply and immediately confirm whether a specific strain is resistant to antibiotics in the field. In particular, a complicated pretreatment process such as proteolysis is not performed, and a complicated identification process of calibrating and then combining the obtained results is not performed. Accordingly, it is possible to realize a method of easily confirming whether antibiotic resistance occurs in just a dozen minutes, compared to a conventional technology in which it takes several days to confirm whether antibiotic resistance occurs, and a simple diagnostic kit used therewith.
-
公开(公告)号:US11236319B2
公开(公告)日:2022-02-01
申请号:US16938318
申请日:2020-07-24
发明人: Michael Kaleko , Sheila Connelly
摘要: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
-
公开(公告)号:US20210380645A1
公开(公告)日:2021-12-09
申请号:US17286125
申请日:2019-10-14
发明人: Qian Zheng
IPC分类号: C07K14/245 , C12N9/86 , C12N15/70
摘要: An efficient protein expression system for expressing a Bt insecticidal protein. Said protein expression system uses Bla (beta-lactamase) as a fusion tag, so that Bt genes unable to be expressed as soluble proteins are expressed as soluble proteins.
-
公开(公告)号:US10982205B2
公开(公告)日:2021-04-20
申请号:US16078040
申请日:2017-02-22
申请人: DA VOLTERRA , BIOASTER
摘要: The present invention relates to an isolated polypeptide having beta-lactamase activity and nucleic acid sequences encoding the polypeptide. The isolated polypeptide of the invention is a Verona integron-encoded metallo-β-lactamase (VIM-2) variant with improved properties such as improved protease stability, stability in intestinal medium, improved activity against one or more antibiotics, improved specific activity and/or improved production in a host cell.
-
-
-
-
-
-
-
-
-